Not investment advice — figures on this page should be verified against official filings before you invest.

Veeda Clinical Research Limited (CRO)

Medical Equipment/Supplies/Accessories Unlisted

ISIN: INE01HQ01026 WittyScore: 0.0/10 Min lot: 100 sh Website

Current Price 23 Aug 2026

₹0

▲ ₹0.00 (+0.00%) this week

Min lot: 100 shares · Total: ₹42,800

Get Quote on WhatsApp Fill inquiry form instead →

Trade

Quantity

Total Amount

Min lot: 100 shares · ₹428.00 per share

₹428

Price

₹2,989.6 Cr

Market Cap

-456.4x

P/E

0.0/10

WittyScore

₹428

52W High

₹428

52W Low

Price movement

Veeda Clinical Research Limited (CRO) unlisted price history

Indicative levels from dealer bids and asks.

Indicative dealer levels. Unlisted prices are negotiated, not exchange-quoted.

About the company

About Veeda Clinical Research Limited (CRO)

Veeda Clinical Research Limited, established in 2004, is a contract research organisation (CRO) based in India that provides clinical research services to pharmaceutical and biotech companies worldwide. Its service range covers bioavailability and bioequivalence studies, phase I-IV clinical trials, clinical data management, pharmacovigilance and statistical analysis. Backed by modern facilities and alignment with international regulatory standards, Veeda positions itself around delivering high-quality, ethical research output, and it has built a reputation as a partner for drug development and regulatory submissions across global markets.

Read the full company profile

Fundamentals

Key metrics and identifiers

Share Price: ₹428.00
Lot Size: 100 shares
52W High: ₹428.00
52W Low: ₹428.00
Market Cap: ₹2,989.6 Cr
P/E: -456.4x
P/B: 1.46x
Debt-to-Equity: 0.21
ROE: -0.3%
Book Value: ₹292.68
EPS: ₹-0.94
Total Shares: 7.0 Cr
ISIN: INE01HQ01026
Depository: Both
Founded: 2004

Verify identifiers and figures against official filings.

Financials

Financial Performance (₹ Cr)

From reported financials — verify against audited annual reports.

Particulars	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue from operations	288.0	409.6	388.8	609.7	715.5
Other Income	5.1	10.6	19.2	11.4	16.9
Total Revenue	293.1	420.2	408.0	621.1	732.4
Total Expenditure	261.6	358.1	404.7	686.7	725.1
Operating Profit	66.5	114.1	71.2	136.4	226.3
Interest	9.6	13.9	14.6	54.3	62.0
Depreciation	25.4	38.0	53.4	147.7	156.9
Profit Before Tax	31.5	62.1	3.3	-65.5	7.3
Tax	15.5	17.1	3.7	1.3	13.9
Profit After Tax	50.5	42.4	-0.4	-66.8	-6.6

Particulars	FY2022	FY2023	FY2024	FY2025	FY2026
Total Assets	677.5	734.8	2,040.2	1,863.2	2,044.4
Current Assets	312.4	294.2	557.2	462.0	581.5
Non-Current Assets	365.1	440.6	1,483.0	1,401.3	1,462.9
Total Debt	60.1	48.6	261.7	406.0	421.4
Current Liabilities	151.4	181.0	512.1	433.4	443.3
Non-Current Liabilities	88.9	90.8	463.1	568.1	480.7
Shareholders' Equity	437.3	462.9	1,065.0	861.8	2,044.4

Particulars	FY2022	FY2023	FY2024	FY2025	FY2026
Cash from Operations	35.9	105.7	58.9	33.3	238.7
Cash from Investing	-153.7	-126.3	-446.9	-149.3	-56.2
Cash from Financing	162.6	-1.2	399.7	91.4	-105.9
Free Cash Flow	7.2	29.8	-24.4	5.5	210.2

Process

How to buy unlisted shares

Submit KYC

Share your CML copy + PAN + Cancelled Cheque + Aadhaar for verification. Takes ~30 minutes.

Transfer Payment

Transfer to the verified StockWitty company account (never personal). UPI, NEFT, RTGS accepted.

Receive Shares

Shares credited to your demat (CDSL or NSDL) the same day. Independent ISIN verification available.

Trustpilot Read our reviews

Google Reviews Rated by investors

ISIN Verified CDSL / NSDL demat

CA Reviewed Data checked for accuracy

Human Support Real people, no bots

Disclaimer: StockWitty is a distributor of unlisted and pre-IPO shares, not a SEBI-registered investment adviser. Unlisted shares are illiquid and high-risk, prices are negotiated and an IPO may be delayed or never happen. Nothing on this page is investment advice.